BTIG Keeps a Hold Rating on Irhythm Technologies (IRTC)

BTIG analyst Marie Thibault maintained a Hold rating on Irhythm Technologies (IRTCResearch Report) today. The company’s shares closed last Tuesday at $76.25, close to its 52-week low of $70.35.

According to TipRanks.com, Thibault is a 5-star analyst with an average return of 66.6% and a 55.9% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Edwards Lifesciences, and Boston Scientific.

Currently, the analyst consensus on Irhythm Technologies is a Hold with an average price target of $97.80, a 29.5% upside from current levels. In a report issued on May 17, Oppenheimer also maintained a Hold rating on the stock.

See today’s analyst top recommended stocks >>

Based on Irhythm Technologies’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $74.31 million and GAAP net loss of $27.78 million. In comparison, last year the company earned revenue of $63.54 million and had a GAAP net loss of $9.07 million.

Based on the recent corporate insider activity of 51 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of IRTC in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

iRhythm Technologies, Inc. is a commercial-stage digital healthcare company, which engages in the development of monitoring and diagnostic solutions for detection of cardiac arrhythmias. It offers ZIO which diagnose many arrhythmias, avoiding multiple indeterminate tests, allowing for appropriate medical intervention, and prevents serious downstream medical events. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.